初诊淋巴结阳性乳腺癌新辅助治疗后腋窝手术的国际EUBREAST调查
共记录45个国家349名医生的回答:cN1转为ycN0者最常用靶向腋窝清扫(54.2%),ycN+者66.8%选择腋窝淋巴结清扫(ALND)。
要点
- cN1转为ycN0患者中靶向腋窝清扫最常用,占54.2%。
- ycN+肿瘤患者中66.8%的受访者首选ALND。
- 腋窝手术方式国际差异大,亟需研究数据标准化指南。
核心结论
- cN+乳腺癌NAT后腋窝手术方式在国际上存在广泛异质性,亟需临床研究数据以标准化指南。
主要发现
- cN1转为ycN0患者NAT后最常用的腋窝手术为靶向腋窝清扫(54.2%),其次为单纯前哨淋巴结活检(SLNB)(20.9%)、1-2站ALND(18.4%)、1-3站ALND(4%)和靶向淋巴结活检(2.5%)。
- 单纯SLNB时最常用双示踪剂(62.3%)。
- ycN+肿瘤患者中66.8%的受访者首选ALND。
关键数值与推荐
- cN1转为ycN0:靶向腋窝清扫54.2%,单纯SLNB 20.9%,1-2站ALND 18.4%,1-3站ALND 4%,靶向淋巴结活检2.5%。
- 单纯SLNB使用双示踪剂者占62.3%。
- ycN+肿瘤:66.8%受访者首选ALND。
临床怎么用
- 调查显示cN1转为ycN0时靶向腋窝清扫应用最广,单纯SLNB亦占一定比例,提示临床决策需结合腋窝状态个体化。
- 对ycN+患者多数受访者仍选择ALND,提示降阶梯手术应限于研究或严格选择人群。
局限性
- 本文为调查第一部分,仅反映受访医生对临床场景的选择,未报告患者实际结局。
- 调查通过学会自愿参与,可能存在选择偏倚,且未涉及长期肿瘤学结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus on axillary management after neoadjuvant therapy (NAT) in patients with clinically node-positive (cN+) breast cancer. To investigate current clinical practice, an international survey was conducted among breast surgeons and radiation oncologists. The aim of the first part of the survey was to provide a snapshot of international discrepancies regarding axillary surgery in this context. METHODS: The European Breast Cancer Research Association of Surgical Trialists (EUBREAST) developed a web-based survey containing 39 questions describing clinical scenarios in the setting of axillary management in patients with cN1 disease converting to ycN0 after NAT. The survey was then distributed to breast surgeons and radiation oncologists via 14 breast cancer societies between April and October 2021. RESULTS: Responses from 349 physicians in 45 countries were recorded. The most common post-NAT axillary surgery in patients with cN1 disease converting to ycN0 was targeted axillary dissection (54.2 per cent), followed by sentinel lymph node biopsy (SLNB) alone (20.9 per cent), level 1-2 axillary lymph node dissection (ALND) (18.4 per cent), level 1-3 ALND (4 per cent), and targeted lymph node biopsy (2.5 per cent). For SLNB alone, dual tracers were most commonly used (62.3 per cent). Management varied widely in patients with ambiguous axillary status before initiation of treatment or a residual metastatic burden in the axilla after NAT. In patients with ycN+ tumours, ALND was the preferred surgical approach for 66.8 per cent of respondents. CONCLUSION: These results highlight the wide heterogeneity in surgical approaches to the axilla after NAT. To standardize the guidelines, further data from clinical research are urgently needed, which underlines the importance of the ongoing AXSANA (EUBREAST-3) study.
引用
- Gasparri ML, de Boniface J, Poortmans P, et al. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg. 2022. PMID: 35766257. doi:10.1093/bjs/znac217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。